Skip to main content

Uptravi Side Effects

Generic name: selexipag

Medically reviewed by Drugs.com. Last updated on Sep 14, 2023.

Note: This document contains side effect information about selexipag. Some dosage forms listed on this page may not apply to the brand name Uptravi.

Applies to selexipag: oral tablet. Other dosage forms:

Serious side effects of Uptravi

Along with its needed effects, selexipag (the active ingredient contained in Uptravi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking selexipag:

Incidence not known

Other side effects of Uptravi

Some side effects of selexipag may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to selexipag: intravenous injection, oral tablet.

Cardiovascular

Very common (10% or more): Flushing (up to 12%), sinus tachycardia (up to 11.3%)

Common (1% to 10%): Hypotension

Frequency not reported: Hot flush

Postmarketing reports: Symptomatic hypotension[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 42%), nausea (up to 34%), vomiting (up to 18%)

Common (1% to 10%): Abdominal pain, dyspepsia, abdominal discomfort

Frequency not reported: Ascites[Ref]

General

The most frequently reported side effects included headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing.[Ref]

Dermatologic

Very common (10% or more): Rash (11%)

Common (1% to 10%): Urticaria, erythema[Ref]

Endocrine

Common (1% to 10%): Hyperthyroidism, thyroid stimulating hormone decreased[Ref]

Hematologic

Common (1% to 10%): Anemia, hemoglobin decreased[Ref]

Local

Frequency not reported (injection): Infusion-site reactions (erythema, redness, pain, swelling)

Metabolic

Common (1% to 10%): Appetite decreased[Ref]

Musculoskeletal

Very common (10% or more): Jaw pain (26%), pain in extremity (up to 17%), myalgia (up to 16%), arthralgia (up to 11%)

Common (1% to 10%): Musculoskeletal pain, neck pain

Frequency not reported: Bone pain[Ref]

Nervous system

Very common (10% or more): Headache (up to 65%)

Frequency not reported: Burning sensation[Ref]

Ocular

Common (1% to 10%): Eye pain, retinal disorder[Ref]

Oncologic

Common (1% to 10%): Malignancy[Ref]

Other

Common (1% to 10%): Asthenia, pyrexia, pain, influenza, weight decreased[Ref]

Renal

Frequency not reported: Acute renal failure

Respiratory

Very common (10% or more): Nasopharyngitis (13%)

Common (1% to 10%): Nasal congestion

Frequency not reported: Pulmonary veno-occlusive disease[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.